-transparent.png){kind=logo}
Treatment of acute viral hepatitis B is symptomatic, fulminant cases may require liver transplantation. In chronic hepatitis B interferon (IFN)-alpha will induce sustained response rates of 30-40%. Nucleoside analogues such as famciclovir or lamivudine appear to be promising for treatment in non-responders or cirrhotic and immunosuppressed patients. IFN-alpha may reduce the rate of chronic courses in acute hepatitis C infections. Chronic hepatitis C patients with elevated ALT activities, positive serum HCV RNA and portal or bridging fibrosis on biopsy are recommended for treatment with IFN-alpha. Sustained responses are observed in less than 20% of treated patients. Retreatment with IFN-alpha may be indicated in non-responders or in case of relapse. Combination therapy of IFN-alpha plus ribavirin may emerge as treatment of choice for patients with a relapse in the near future.
H R Bruch, and
U Höhner, and
R Müller
June 2023,
Journal of personalized medicine,
H R Bruch, and
U Höhner, and
R Müller
April 2015,
Revue medicale suisse,
H R Bruch, and
U Höhner, and
R Müller
January 2022,
Casopis lekaru ceskych,
H R Bruch, and
U Höhner, and
R Müller
January 2010,
Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology,
H R Bruch, and
U Höhner, and
R Müller
November 2008,
Bulletin de l'Academie nationale de medecine,
H R Bruch, and
U Höhner, and
R Müller
August 1982,
The Nebraska medical journal,
H R Bruch, and
U Höhner, and
R Müller
March 1991,
Revue medicale de la Suisse romande,
H R Bruch, and
U Höhner, and
R Müller
January 2006,
Scandinavian journal of gastroenterology. Supplement,
H R Bruch, and
U Höhner, and
R Müller
April 2007,
International journal of colorectal disease,
H R Bruch, and
U Höhner, and
R Müller
September 2004,
Deutsche medizinische Wochenschrift (1946),
